Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

701,361 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 70,137
1.20240140922FUSED HETEROBICYCLIC ANTIVIRAL AGENTS
US - 02.05.2024
Int.Class C07D 285/36
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
285Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
36Seven-membered rings
 Appl.No 18236560 Applicant ENANTA PHARMACEUTICALS, INC. Inventor Samuel Bartlett

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:

embedded image

which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

2.20240140932CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS
US - 02.05.2024
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
 Appl.No 18335480 Applicant GLOBAL BLOOD THERAPEUTICS, INC. Inventor QING XU

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

3.20240140925METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER
US - 02.05.2024
Int.Class C07D 307/77
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
77ortho- or peri-condensed with carbocyclic rings or ring systems
 Appl.No 18152968 Applicant NAN YA PLASTICS CORPORATION Inventor TE-CHAO LIAO

A method for manufacturing a low-viscosity hardener is provided. The method includes the followings steps: providing a hardener crude product; and subjecting the hardener crude product and an alkaline catalyst to an isomerization reaction, so as to obtain the low-viscosity hardener. The hardener crude product contains 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride, and a weight ratio of the 3-methyltetrahydrophthalic anhydride to the 4-methyltetrahydrophthalic anhydride ranges from 7:3 to 3:7. A viscosity of the low-viscosity hardener ranges from 30 cps to 50 cps.

4.20240140930PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES
US - 02.05.2024
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No 18478060 Applicant NeuroPn Therapeutics Inc. Inventor Ish Khanna

Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolase.

5.20240140933OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER
US - 02.05.2024
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
 Appl.No 18514478 Applicant Hoffmann-La Roche Inc. Inventor Fabian DEY

The present invention relates to compounds of formula (I),

embedded image

    • wherein R1 to R3, A1 to A3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

6.WO/2024/087720COMPOUND FOR TLR8 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 02.05.2024
Int.Class C07D 215/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
20Oxygen atoms
 Appl.No PCT/CN2023/104858 Applicant TOLL BIOTECH CO.LTD.(BEIJING) Inventor GAO, Meng
Provided in the present invention are a compound for a TLR8 inhibitor, and a preparation method therefor and the use thereof, which relate to the technical field of small molecule pharmaceutical compounds. The compound of the present invention solves the technical problems of poor solubility and low inhibition effect of an existing small molecule compound for a TLR8 inhibitor, and achieves the technical effects of high solubility and strong inhibition effect on TLR8.
7.WO/2024/088110HETEROCYCLIC MACROCYCLIC COMPOUND CONTAINING INDAZOLE STRUCTURE AND USED AS PROTEIN KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR
WO - 02.05.2024
Int.Class C07D 498/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
12in which the condensed system contains three hetero rings
18Bridged systems
 Appl.No PCT/CN2023/124971 Applicant FUDAN UNIVERSITY Inventor SHAO, Liming
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally provided are a pharmaceutically acceptable salt, prodrug, and solvate of the compound. Further provided is a use in preparing a drug for treating or preventing disorders or diseases mediated by targets such as activated or resistant mutant forms of ALK; preferably, the disorders or diseases mediated by the activated or resistant mutant forms (including but not limited to EML4-ALK fusion mutation) of ALK are: lung cancer, ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastrointestinal stromal tumor, thyroid cancer, bile duct cancer, endometrial cancer, kidney cancer, anaplastic large cell lymphoma, acute myeloid leukemia, multiple myeloma, or mesothelioma, etc.
8.WO/2024/088395BRIDGED-RING COMPOUND AND PHARMACEUTICAL USE THEREOF
WO - 02.05.2024
Int.Class C07D 233/86
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
86Oxygen and sulfur atoms, e.g. thiohydantoin
 Appl.No PCT/CN2023/127198 Applicant MEDSHINE DISCOVERY INC. Inventor LUO, Yunfu
Disclosed in the present invention are a series of bridged-ring compounds and a pharmaceutical use thereof, and in particular, disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
9.WO/2024/088410PREPARATION METHOD FOR LOW-COLOR NUMBER, LOW-ODOR POLYISOCYANATE CURING AGENT
WO - 02.05.2024
Int.Class C07D 251/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
251Heterocyclic compounds containing 1,3,5-triazine rings
02not condensed with other rings
12having three double bonds between ring members or between ring members and non-ring members
26with only hetero atoms directly attached to ring carbon atoms
30Only oxygen atoms
34Cyanuric or isocyanuric esters
 Appl.No PCT/CN2023/127304 Applicant WANHUA CHEMICAL GROUP CO., LTD Inventor LIU, Wei
Disclosed is a preparation method for a low-color number, low-odor polyisocyanate curing agent. The preparation method comprises a step of carrying out a polymerization reaction on a diisocyanate monomer under the action of a trimerization catalyst in a polymerization reaction kettle with continuously flowing inert gas, an upper head of the polymerization reaction kettle being provided with an inert gas inlet pipe, the inert gas inlet pipe being an insertion pipe, and the upper head of the polymerization reaction kettle also being provided with an inert gas outlet and a central stirring shaft; the insertion opening position (A) of the inert gas inlet pipe and the inert gas outlet position (B) on the surface of the upper head form an angle α (∠ACB) with the fixed position (C) of the central stirring shaft projected onto the plane on the upper head surface, where 30°≤α≤180°. The present application can achieve stable catalytic activity of a catalyst by means of controlling the use of nitrogen during the reaction process, which is conducive to stable process control, resulting in a low color number and reduced amine odor in the obtained product.
10.WO/2024/089190PRUNE1 INHIBITORS AND THERAPEUTIC USE THEREOF
WO - 02.05.2024
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/EP2023/079960 Applicant CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE SCARL Inventor ZOLLO, Massimo
There are disclosed compounds able to modulate and specifically inhibit the activity of Prune1 protein, pharmaceutical compositions containing them and the use thereof alone or in combination with chemotherapeutic agents in the prevention or treatment of Prune1- overexpressing tumors and metastasis.
# -